Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials

OBJECTIVE: To investigate if extracellular matrix (ECM) blood-based biomarkers reflect the pharmacodynamic effect and response to TNF-α inhibitor therapy (adalimumab, ADA), in patients with axial spondyloarthritis (axSpA). METHODS: We investigated ECM biomarkers in two randomized, double-blind, plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Port, Helena, Holm Nielsen, Signe, Frederiksen, Peder, Madsen, Sofie Falkenløve, Bay-Jensen, Anne-Christine, Sørensen, Inge Juul, Jensen, Bente, Loft, Anne Gitte, Madsen, Ole Rintek, Østergaard, Mikkel, Pedersen, Susanne Juhl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463764/
https://www.ncbi.nlm.nih.gov/pubmed/37626399
http://dx.doi.org/10.1186/s13075-023-03132-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463764/
https://www.ncbi.nlm.nih.gov/pubmed/37626399
http://dx.doi.org/10.1186/s13075-023-03132-5

Ejemplares similares